Background The purpose of this study was to identify mechanisms of innate resistance to an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of …

Colorectal cancer (CRC) originates in the tissues of the colon (the longest part of the large
intestine), rectum and appendix, and is also known as colon cancer. Most CRCs are …

Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine
kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking …

Abstract The Epidermal Growth Factor Receptor (EGFR) is a central regulator of cell
proliferation and differentiation in human cancers and is frequently overexpressed in many …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …

Epidermal growth factor receptor (EGFR) is a validated target in different human
malignancies. EGFR tyrosine kinase inhibitors (TKIs) are known to contribute considerably …

The development of acquired resistance to EGFR inhibitors is emerging as a potential
treatment barrier for EGFR targeted therapies. Efforts to better understand underlying …

Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

Cancer is one of the most feared diseases in the world, being ranked as the second leading
cause of death from disease. It is also observed that both chemotherapy and radiotherapy …

Acquired resistance to targeted therapy remains a major limitation to clinical benefit in
oncology. Understanding mechanisms of resistance can potentially lead to novel strategies …